Terminated PHASE4 INTERVENTIONAL 2-arm NCT00720902

Adult Growth Hormone Deficiency and Cardiovascular Risk

Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas

Sponsor: Columbia University

Interventions Blood draws Carotid ultrasound Endothelial cell biopsy MRI growth hormone releasing hormone (GHRH) & arginine

Updated 7 times since 2017 Last updated: Oct 24, 2022 Started: Feb 28, 2007 Primary completion: Mar 31, 2010 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

poor enrollment

Other terminated trials from Columbia University

See all terminations from Columbia University

Other Growth Hormone Deficiency trials with similar outcome

Browse all Growth Hormone Deficiency trials

Listed as NCT00720902, this PHASE4 trial focuses on Growth Hormone Deficiency and remains terminated or withdrawn. Sponsored by Columbia University, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jul 2024 [monthly]

Terminated PHASE4

Phase: NA → PHASE4
Jan 2021 — Dec 2022 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Columbia University

Data source: Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States